Business Description
IQVIA Holdings Inc
NAICS : 621399
SIC : 8099
ISIN : US46266C1053
Total Employee Number:
93,000Compare
Compare
Traded in other countries / regions
IQV.USA0JDM.UKI1QV34.BrazilQTS.GermanyIQVH.AustriaIQV.Mexico1IQV.Italy IPO Date
2018-01-18Description
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 2.58 | |||||
Debt-to-EBITDA | 4.57 | |||||
Interest Coverage | 3.08 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.93 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.5 | |||||
3-Year EBITDA Growth Rate | 9.4 | |||||
3-Year EPS without NRI Growth Rate | 5.5 | |||||
3-Year FCF Growth Rate | 12.4 | |||||
3-Year Book Growth Rate | 7.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.89 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.84 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 91.18 | |||||
9-Day RSI | 79.83 | |||||
14-Day RSI | 72.23 | |||||
3-1 Month Momentum % | 7.96 | |||||
6-1 Month Momentum % | -17.17 | |||||
12-1 Month Momentum % | 15.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.75 | |||||
Quick Ratio | 0.75 | |||||
Cash Ratio | 0.25 | |||||
Days Sales Outstanding | 33.43 | |||||
Days Payable | 97.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3 | |||||
Shareholder Yield % | -1.09 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.99 | |||||
Operating Margin % | 13.99 | |||||
Net Margin % | 8.33 | |||||
EBITDA Margin % | 21.16 | |||||
FCF Margin % | 12.72 | |||||
OCF Margin % | 16.26 | |||||
ROE % | 22.6 | |||||
ROA % | 4.8 | |||||
ROIC % | 7.22 | |||||
3-Year ROIIC % | 7.96 | |||||
ROC (Joel Greenblatt) % | 291.09 | |||||
ROCE % | 11.27 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 25.36 | |||||
Forward PE Ratio | 14.99 | |||||
PE Ratio without NRI | 16.87 | |||||
Shiller PE Ratio | 37.3 | |||||
Price-to-Owner-Earnings | 17.33 | |||||
PEG Ratio | 1.35 | |||||
PS Ratio | 2.11 | |||||
PB Ratio | 5.49 | |||||
Price-to-Free-Cash-Flow | 16.59 | |||||
Price-to-Operating-Cash-Flow | 12.98 | |||||
EV-to-EBIT | 20.41 | |||||
EV-to-Forward-EBIT | 17.87 | |||||
EV-to-EBITDA | 13.64 | |||||
EV-to-Forward-EBITDA | 12.14 | |||||
EV-to-Revenue | 2.89 | |||||
EV-to-Forward-Revenue | 2.68 | |||||
EV-to-FCF | 21.9 | |||||
Price-to-GF-Value | 0.82 | |||||
Price-to-Projected-FCF | 1.18 | |||||
Price-to-DCF (Earnings Based) | 0.59 | |||||
Price-to-DCF (FCF Based) | 0.7 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.63 | |||||
Earnings Yield (Greenblatt) % | 4.9 | |||||
FCF Yield % | 6.24 | |||||
Forward Rate of Return (Yacktman) % | 15.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IQVIA Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 16,632 | ||
| EPS (TTM) ($) | 8.07 | ||
| Beta | 0.5907 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | -0.01 | ||
| Volatility % | 40.41 | ||
| 14-Day RSI | 72.23 | ||
| 14-Day ATR ($) | 8.458595 | ||
| 20-Day SMA ($) | 181.5253 | ||
| 12-1 Month Momentum % | 15.13 | ||
| 52-Week Range ($) | 150 - 246.81 | ||
| Shares Outstanding (Mil) | 166.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IQVIA Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IQVIA Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 09:00 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-22 09:00 | In 21 days | ||
| Second quarter earnings results for 2026 | 2026-07-22 | In 20 days | ||
| Jeeries Global Healthcare Conference | 2026-06-03 09:20 | 179.94 (-4.10%) | ||
| Bank of America Health Care Conference | 2026-05-13 13:40 | 174.45 (+2.30%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 09:00 | 157.65 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 157.65 (+0.00%) | ||
| General meeting for 2026 | 2026-04-23 09:00 | 175.77 (-1.60%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-12 09:30 | 170.84 (-0.44%) |
Show
Entries
IQVIA Holdings Inc Frequently Asked Questions
What is IQVIA Holdings Inc(LTS:0JDM)'s stock price today?
The current price of LTS:0JDM is $203.41. The 52 week high of LTS:0JDM is $246.81 and 52 week low is $150.00.
When is next earnings date of IQVIA Holdings Inc(LTS:0JDM)?
The next earnings date of IQVIA Holdings Inc(LTS:0JDM) is 2026-07-22 Est..
Does IQVIA Holdings Inc(LTS:0JDM) pay dividends? If so, how much?
IQVIA Holdings Inc(LTS:0JDM) does not pay dividend.
Press Release
Articles on IQVIA Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers